Advertisement

Search Results

Advertisement



Your search for ,are matches 22257 pages

Showing 21051 - 21100


bladder cancer

‘Wound Response’ of Cancer Stem Cells May Explain Chemoresistance in Bladder Cancer

A novel mechanism—similar to how normal tissue stem cells respond to wounding—might explain why bladder cancer stem cells actively contribute to chemoresistance after multiple cycles of chemotherapy drug treatment. Targeting this “wound response” of cancer stem cells can...

skin cancer

Telomere Length Genes Are Associated With Melanoma Risk

Longer telomeres have been associated with increased risk of melanoma. In a GenoMEL Consortium genome-wide association study reported in the Journal of the National Cancer Institute, Iles et al found that several single-nucleotide polymorphisms (SNPs) previously associated with leukocyte telomere...

hematologic malignancies

FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera

The U.S. Food and Drug Administration (FDA) today approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too...

breast cancer
issues in oncology

Effect of Computer-Aided Detection in Mammography Screening on Cost and DCIS Diagnosis in Medicare Population

In a study reported in a research letter in JAMA Surgery, Fenton et al found that a sizable proportion of ductal carcinoma in situ (DCIS) diagnoses are attributable to computer-aided detection in mammography screening in the Medicare population and that use of computer-aided detection in this...

Ixazomib Receives Breakthrough Therapy Designation for Relapsed or Refractory Systemic Light-Chain Amyloidosis

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to Takeda Pharmaceuticals’ investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain amyloidosis. This is the first proteasome inhibitor...

kidney cancer
kidney cancer

Surveillance Guidelines Miss 30% of Renal Cell Carcinoma Recurrences After Nephrectomy

In a study reported in the Journal of Clinical Oncology, Stewart et al found that 30% or more of renal cell carcinoma recurrences were missed using National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines for surveillance after surgery for renal cell...

leukemia

FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...

breast cancer
issues in oncology

Risk-Based Screening Misses Over 75% of Invasive Breast Cancers in Women in Their 40s

A study of breast cancers detected with screening mammography found that strong family history and dense breast tissue were commonly absent in women between the ages of 40 and 49 diagnosed with breast cancer. Results of the study were presented today at RSNA 2014, the annual meeting of the...

issues in oncology

Bisphosphonates May Block the Development of HER-Driven Tumors, Preventing Breast, Lung, and Colon Cancers

Two studies have found that bisphosphonates may be effective in preventing certain cancers—including lung, breast, and colon—by blocking abnormal growth signals passed through HER family receptors. The studies suggest that bisphosphonates, the most commonly prescribed medications for...

breast cancer
issues in oncology

3D Mammography Improves Cancer Detection in Dense Breasts

A new study presented at RSNA 2014, the annual meeting of the Radiological Society of North America, has found that digital breast tomosynthesis, also known as three-dimensional (3D) mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women ...

issues in oncology

CONCORD-2 Study Reveals Wide Variability in Global Cancer Survival Rates

As reported in The Lancet by Allemani et al, the CONCORD-2 study of global cancer survival indicates improvements in survival in many countries in colorectal, breast, and prostate cancers, persistent poor outcomes in lung and liver cancers, and wide variability in survival in many cancers. The...

breast cancer

DNA Vaccine Targeting Mammaglobin-A Produces Robust Immune Response in Metastatic Breast Cancer

In a phase I study, a DNA vaccine targeting the breast cancer–associated antigen mammaglobin-A (MAM-A) was found to be safe and effective in eliciting immune responses in women with metastatic breast cancer. Preliminary evidence also suggests that the vaccine improved progression-free...

integrative oncology

Despite Popularity of Alternative Medicine, Most U.S. Oncologists Do Not Discuss Herb and Supplement Use With Their Patients

Available data indicate that a majority of cancer patients use complementary and alternative medicine. In a study reported in the Journal of Clinical Oncology, Lee et al found that oncologists responding to a survey on herb and supplement use did not discuss herb and supplement use with most of...

leukemia

FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy

The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to JCAR015, an investigational chimeric antigen receptor therapy developed by Juno Therapeutics. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed...

breast cancer
issues in oncology

More Than 40% of U.S. Women Have Mammographically Dense Breasts

In a study reported in the Journal of the National Cancer Institute, Sprague et al found that more than 40% of U.S. women have mammographically dense breasts, with the prevalence being inversely proportional to age and body mass index (BMI). As noted by the authors: “National legislation is...

lymphoma

Benefit of Extended Rituximab Exposure in Poor-Prognosis Elderly Patients With Diffuse Large B-Cell Lymphoma

In the phase II SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group reported in the Journal of Clinical Oncology, Pfreundschuh et al found that extended rituximab (Rituxan) exposure in patients aged > 60 years with poor-prognosis diffuse large B-cell lymphoma was...

breast cancer
gynecologic cancers

Low Risk of Breast Cancer After Ovarian Cancer in Women With BRCA Mutation

In a retrospective single-institution study reported in JAMA Surgery, Gangi et al found a low risk of breast cancer after diagnosis of ovarian cancer in women harboring BRCA mutations.   The study involved 364 women who had BRCA mutation testing for stage I to IV epithelial ovarian...

gynecologic cancers

FDA Warns Against Using Laparoscopic Power Morcellators to Treat Uterine Fibroids

The U.S. Food and Drug Administration (FDA) today announced that it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April 2014, the FDA warned against using...

survivorship

Adult Survivors of Retinoblastoma Experience Few Cognitive or Social Setbacks

Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment, according to a study by Brinkman et al published in Cancer. The findings offer good news for patients, but the...

kidney cancer

High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...

cns cancers

Immune Checkpoint Inhibitors May Work in Brain Cancers

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva (Abstract 1O). The novel research shows that brain metastases of tumor infiltrating lymphocytes, providing an immunoactive...

leukemia
issues in oncology

Exposure to Hookah Smoke Doubles Benzene Uptake, Potentially Increasing Risk for Leukemia

Findings from a new study show that hookah smokers and nonsmokers exposed to hookah (or waterpipe) secondhand tobacco smoke at social events in hookah lounges and in private homes had significant increases in uptake of benzene, a leukemogen that causes lymphohematopoietic cancers, especially acute...

supportive care

FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties

The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate (Hysingla ER), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product...

issues in oncology
gynecologic cancers

Researchers Identify Biomarker of Response to New Ovarian Cancer Drug

Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...

breast cancer

About 25% of Patients Undergoing Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery

“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online in JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility...

prostate cancer

Galeterone Shows Activity in Variant Form of Castration-Resistant Prostate Cancer

Results from the ARMOR2 of the anticancer drug galeterone shows that it is successful in lowering prostate-specific antigen (PSA) levels in men with a variant form castration-resistant prostate cancer. The findings, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...

kidney cancer
kidney cancer

Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy

Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...

leukemia

IDH1 Inhibitor Demonstrates Anticancer Activity in Advanced Leukemia

A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation. The...

leukemia

FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...

breast cancer

High Rate of Tumor Marker Assessment in Older Early-Stage Breast Cancer Survivors

Current guidelines discourage tumor marker assessment in surveillance of nonmetastatic breast cancer. In a study reported in the Journal of Clinical Oncology, Ramsey et al found that > 40% of Medicare patients with early-stage breast cancer had at least one tumor marker assessment and that...

issues in oncology

Metabolic ‘Reprogramming’ by the p53 Gene Family Leads to Tumor Regression

Scientists have found that altering members of the p53 gene family, known as tumor-suppressor genes, causes rapid regression of tumors that are deficient in or totally missing p53. Study results suggest existing diabetes drugs, which impact the same gene-protein pathway, might be effective for...

Proton Radiotherapy Safe and Effective in Pediatric Rhabdomyosarcoma

In a phase II study reported in the Journal of Clinical Oncology, Ladra et al found that proton radiotherapy was a safe and effective treatment in pediatric rhabdomyosarcoma. Proton radiotherapy can substantially reduce radiotherapy doses to normal tissue compared with conventional photon...

skin cancer

Interactions Between Genetic Variants and Sun Behaviors May Influence Future Melanoma Risk

The combination of different patterns of sun exposure experienced by children and biomarkers of melanoma risk, such as the number of freckles or moles that develop as a result, may play a large role in future melanoma risk, a study investigating gene and environmental interactions has found....

health-care policy
issues in oncology

ASCO Calls for Major Medicaid Reform to Improve Quality Cancer Care for Low-Income Americans

ASCO issued its new Policy Statement on Medicaid Reform yesterday, which calls for major changes to the program to ensure access to high-quality cancer care for all low-income individuals. The Society’s recommendations call for Medicaid expansion in all 50 states to close coverage gaps,...

lung cancer

Outcomes With Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy in Medicare Patients With Early-Stage NSCLC

In a study on use of the most common definitive therapies for non–small cell lung cancer (NSCLC) in Medicare patients reported in JAMA Surgery, Shirvani et al found that lobectomy was associated with improved outcome vs sublobar resection and that stereotactic ablative radiotherapy may be of...

sarcoma
issues in oncology

Gene Sequencing Projects Link Two Mutations to Ewing Sarcoma Subtype With Poor Prognosis

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma and that define a subtype of the cancer associated with reduced survival. The research, conducted by the St. Jude Children’s Research Hospital-Washington University...

gynecologic cancers
issues in oncology

HPV Vaccine Uptake Among Girls Is Lowest in States With Highest Rates of Cervical Cancer

The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health...

issues in oncology

Even With Equal Health-Care Access, Cancer Survival Rates Are Worse in American Indians and Alaskan Natives

The 5- and 10-year cancer survival rates were lower among American Indians and Alaskan Natives compared with non-Hispanic whites even when they had approximately equal access to health care, according to data presented at the American Association for Cancer Research (AACR) conference on The Science ...

lung cancer

Video-Assisted Thoracoscopic Surgery Technique for Pneumonectomy Shown to Be Safe

In the largest series of its kind to date, researchers at Roswell Park Cancer Institute (RPCI) have shown that performing thoracoscopic pneumonectomy, removal of the entire lung through a minimally invasive endoscopic approach, at a high-volume center appears to be safe and may provide pain and...

supportive care
issues in oncology
issues in oncology
palliative care

End-of-Life Discussions Are Associated With Longer Survival and Higher Quality of Life

A review of advance care planning and end-of-life communication practices among physicians by the American College of Physicians has found that implementing early discussions about goals of care with seriously ill patients results in better quality of life, reduced use of life-sustaining treatments ...

Olaparib Treatment Yields Promising Response Rates in Patients With BRCA Mutation–Associated Cancers

Olaparib, an experimental twice-daily oral cancer drug, produced an overall tumor response rate of 26% in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to a phase II study reported by Kaufman et al in the Journal of Clinical Oncology. The positive response provides...

colorectal cancer

Number of Young Patients With Newly Diagnosed Colorectal Cancer Anticipated to Double

In the next 15 years, more than 1 in 10 colon cancers and nearly 1 in 4 rectal cancers will be diagnosed in patients younger than the traditional screening age, according to researchers at The University of Texas MD Anderson Cancer Center. This growing public health problem is underscored by data...

breast cancer

No Benefit of Adding Lapatinib to Fulvestrant in Hormone Receptor–Positive Advanced Breast Cancer

In the phase III Cancer and Leukemia Group B (CALGB) 40302/Alliance trial reported in the Journal of Clinical Oncology, Burstein et al found that the addition of the dual EGFR-HER2 inhibitor lapatinib (Tykerb) to endocrine therapy with fulvestrant (Faslodex) did not improve progression-free...

integrative oncology

Study Shows Integrative Medicine Can Relieve Pain and Anxiety for Cancer Inpatients

Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health-care providers. The Penny George Institute for Health and Healing researchers found that integrative medicine therapies can substantially decrease pain and...

gynecologic cancers
gynecologic cancers
issues in oncology

CDC Reports That Millions of U.S. Women Are Not Getting Screened for Cervical Cancer

Despite evidence that cervical cancer screening saves lives, about 8 million women aged 21 to 65 years have not been screened for cervical cancer in the past 5 years, according to a new report from the Centers for Disease Control and Prevention (CDC) published in Morbidity and Mortality Weekly ...

gynecologic cancers

Dual HER2 Blockade With Lapatinib and Trastuzumab Improves Inhibition of Tumor Growth in HER2-Amplified Uterine Serous Carcinoma

In a retrospective analysis utilizing both uterine serous carcinoma cell lines and patient-derived xenografts, dual therapy with lapatinib (Tykerb) and trastuzumab (Herceptin) demonstrated antitumor responses, according to a study by Groeneweg et al in Clinical Cancer Research. Also, the authors...

breast cancer
integrative oncology

New Guidelines Issued on Use of Complementary Therapies for Breast Cancer

More than 80% of breast cancer patients in the United States use complementary therapies following a breast cancer diagnosis, but there has been little science-based guidance to inform clinicians and patients about their safety and effectiveness. In newly published clinical practice guidelines...

gynecologic cancers
gynecologic cancers

Pelvic Radiotherapy May Benefit Some Women With Ovarian Clear Cell Adenocarcinoma

Adjuvant radiotherapy may play a role in the management of ovarian clear cell adenocarcinoma, which appears to be less prone to peritoneal dissemination than other subtypes, according to the results of a small retrospective study reported by Macrie et al in the International Journal of...

prostate cancer

ASCO Endorses AUA/ASTRO Guideline on Adjuvant and Salvage Radiotherapy After Prostatectomy

The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) guideline on the use of adjuvant and salvage radiotherapy after prostatectomy, which was based on a systematic review of medical...

lung cancer
issues in oncology

Crizotinib Highly Active in ROS1-Rearranged NSCLC

In a study reported in The New England Journal of Medicine, Shaw et al found that crizotinib (Xalkori) produced a high response rate in patients with ROS1-rearranged non–small cell lung cancer (NSCLC). Chromosomal rearrangements in ROS1, which encodes the proto-oncogene receptor tyrosine...

Advertisement

Advertisement




Advertisement